Idera Pharmaceuticals, Inc. IDRA
0.43 0.00 (+0.00%)
At closeJan 17, 2023, 4:00 PM EST
0.4201 Day range 0.51
52-week range unavailable
- Market cap
- 26.50M
- Revenue (ttm)
- 49.00K
- Shares out
- 62.36M
- Forward P/E
- -1.04
- Volume
- 371.88K
- Open
- 0.4768
- Previous close
- 0.425
- Day's range
- 0.4201 – 0.51
- Beta
- 1.30
- Analysts
- Hold
- Earnings date
- Nov 14, 2022
2Y -0.4357 (-50.62%)
Key statistics
- Enterprise value
- 57.20M
- PEG ratio
- 0.00
- Price / sales
- 540.84
- Price / book
- 1.21
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 3.37M
- Total cash
- 26.80M
- Total debt
- 625.00K
- Return on equity
- -32.32%
- Short % of float
- 1.04%
- 50-day average
- 6.25
- 200-day average
- 7.36
Analyst view
Consensus: hold
Hold
Price target (mean) —
Ratings (0m) 7 7 buy · 0 hold · 0 sell
- Strong buy2
- Buy5
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 14, 2022
Expected Nov 14, 2022. Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2022 | Sep 1, 2022 | 0.00 | — | — | — |
| Aug 9, 2022 | Jun 1, 2022 | 0.00 | — | — | — |
| May 5, 2022 | Mar 1, 2022 | 0.00 | — | — | — |
| Mar 31, 2022 | Dec 1, 2021 | 0.00 | — | — | — |
| Nov 8, 2021 | Sep 1, 2021 | 0.00 | — | — | — |
| Aug 9, 2021 | Jun 1, 2021 | -0.21 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 19, 2021 | Wedbush | down | Outperform | Neutral |
| Mar 19, 2021 | Barclays | down | Overweight | Equal-Weight |
| Mar 19, 2021 | JMP Securities | down | Outperform | Market Perform |
| Mar 19, 2021 | HC Wainwright & Co. | down | Buy | Neutral |
| Mar 19, 2021 | JP Morgan | down | Overweight | Neutral |
| Nov 25, 2020 | Barclays | init | — | Overweight |
About Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration agreement with Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- iderapharma.com
News
Energy Recovery Wins “Breakthrough Innovation Award” at IDRA World Congress 
Stocks That Hit 52-Week Lows On Wednesday 
Stocks That Hit 52-Week Lows On Thursday 
Stocks That Hit 52-Week Lows On Thursday 
Why Sunlight Financial Shares Are Trading Lower By 59%, Here Are 54 Stocks Moving In Thursday's Mid-Day Session 
This Healthcare Stock Jumps Around 188%, Here's 83 Biggest Movers From Yesterday 
Why Is NeuroSense Therapeutics Surging By 70%? 46 Stocks Moving In Monday's Mid-Day Session 
Buying Penny Stocks Right Now? 3 Top Tips to Know 
3 Penny Stocks That Are Climbing During Today's Market Selloff 
Why Are Idera Pharmaceuticals Shares Soaring Today
Your note
Sign in to keep a note on IDRA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DOUGHERTY MICHAEL R | Director | Stock Award(Grant) | Jan 10, 2023 | 375,155 |
| GERAGHTY JAMES A. | Director | Stock Award(Grant) | Mar 31, 2021 | 119,543 |
| JORDAN ANDREW R | Officer | Stock Award(Grant) | Jan 5, 2023 | 839,142 |
| KIRBY JOHN J. | Chief Financial Officer | Stock Award(Grant) | Jan 5, 2023 | 316,893 |
| LIM BRYANT DAVID | General Counsel | Stock Award(Grant) | Jan 5, 2023 | 309,695 |
| PILLAR INVEST CORP | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Sep 21, 2022 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group, Inc. (The) | 4.06% | 2,533,668 | 1.08M | Sep 29, 2022 |
| Blackrock Inc. | 1.41% | 879,282 | 373.69K | Sep 29, 2022 |
| Geode Capital Management, LLC | 1.28% | 795,606 | 338.13K | Sep 29, 2022 |
| Credit Agricole S.A. | 0.64% | 400,000 | 170.00K | Sep 29, 2022 |
| Hollencrest Capital Management | 0.41% | 258,000 | 109.65K | Sep 29, 2022 |
| Citadel Advisors Llc | 0.37% | 232,640 | 98.87K | Sep 29, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 2.07% | 1,289,896 | 548.21K | Sep 29, 2022 |
| Vanguard Total Stock Market Index Fund | 1.85% | 1,152,186 | 489.68K | Sep 29, 2022 |
| Fidelity Extended Market Index Fund | 0.36% | 224,945 | 95.60K | Nov 29, 2022 |
| Fidelity Total Market Index Fund | 0.15% | 91,027 | 38.69K | Nov 29, 2022 |
| Vanguard Institutional Index-Inst Total Stock Market Ind | 0.10% | 64,212 | 27.29K | Sep 29, 2022 |
| Fidelity Series Total Market Index Fund | 0.09% | 54,014 | 22.95K | Nov 29, 2022 |